Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 121-125

  Kim, Sung Wan ^a   Shin, Il Seon ^a   Kim, Jae Min ^a   Bae, Kyung Yeol ^a   Yang, Su Jin ^a   Yoon, Jin Sang ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Aripiprazole; Depression; Metabolic abnormalities; Prolactin; Schizophrenia; Ziprasidone

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; GLUCOSE; PROLACTIN; QUETIAPINE; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; BECK DEPRESSION INVENTORY; BODY MASS; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DECREASED APPETITE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; FEMALE; GLUCOSE BLOOD LEVEL; HIP CIRCUMFERENCE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; OLIGOMENORRHEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGIC TEST; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL AND OCCUPATIONAL FUNCTIONING ASSESSMENT SCALE; SUBJECTIVE WELL BEING UNDER NEUROLEPTICS; TARDIVE DYSKINESIA; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY SIZE; BODY WEIGHT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HIP; HUMANS; HYPERPROLACTINEMIA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WAKEFULNESS; YOUNG ADULT;

EID: 77953162615     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181d52b85     Document Type: Article

References (48)

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
2. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121.
3. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217.
4. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-627.
5. Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007;27:365-368.
6. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
7. Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;(4):CD006627.
8. Zimbroff D, Warrington L, Loebel A, et al. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. Int Clin Psychopharmacol 2007;22:363-370.
9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press Inc; 1994.
10. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale for schizophrenia. Schizophr Bull 1987;13:261-276.
11. Yi JS, Ahn YM, Shin HK, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
12. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990;3:247-251.
13. Kim YK, Won SD, Lee KM, et al. A study on the reliability and validity of the Korean version of the Calgary Depression Scale for Schizophrenia (K-CDSS). J Korean Neuropsychiatr Assoc 2005;44:446-455.
14. Kim SW, Kim SJ, Yoon BH, et al. Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res 2006;144:57-63.
15. Beck AT, Ward CH, Mendelson M, et al. An inventory of measuring depression. Arch Gen Psychiatry 1961;4:53-63.
16. Hahn HM, Yum TH, Shin YW, et al. Standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc 1986;25:487-502.
17. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' Subjective Well-being under Atypical Antipsychotic Drugs. Schizophr Res 2001;50:79-88. (Pubitemid 32510889)
18. Kim SW, Shin IS, Kim JM, et al. A validation study of the Korean version of Subjective Well-being under Neuroleptic Treatment Scale-Short Form. Korean J Psychopharmacol 2007;18:221-230.
19. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effect. Acta Psychiatr Scand 1970;212(suppl):11-19.
20. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976;534-537.
22. Mace S, Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009;23:773-780.
23. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;(4):CD006569.
24. Morrato EH, Cuffel B, Newcomer JW, et al. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009;29:26-32.
25. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. C. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272.
26. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res 2007;95:247.
27. Nam YY, Kim CS, Ahn CW, et al. Clinical correlates of metabolic syndrome in patients with chronic schizophrenia. Korean J Psychopharmacol 2006;17:335-341.
28. Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009;32:243-249.
29. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
30. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35.
31. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31:1345-1359.
32. Kirk SL, Neill JC, Jones DN, et al. Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. Eur J Pharmacol 2004;505:253-254.
33. Schmidt AW, Lebel LA, Howard HR Jr, et al. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
34. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone study group. Neuropsychopharmacology 1999;20:491-505.
35. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 2008;33:985-994.
36. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 2009;24:229-238.
37. Addington DE, Pantelis C, Dineen M, et al. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65:1624-1633.
38. Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26:157-162.
39. Lee SJ, Kang DH, Hong KS, et al. Naturalistic, retrospective study on clinical experience of ziprasidone in 3 university hospitals. J Korean Neuropsychiatr Assoc 2007;46:214-222.
40. Ahn YM, Lee KY, Kim KS, et al. Body weight gain and metabolic changes in patients with schizophrenia during 12-week randomized treatment of ziprasidone and risperidone. Korean J Psychopharmacol 2007;18:92-102.
41. Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8:195-201.
42. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-1410.
43. Kim SW, Lee SH, Kim SY, et al. Resolution of ziprasidone-induced hyperprolactinemia with aripiprazole. Korean J Psychopharmacol 2009;20:106-110.
44. Sharma A, Ramaswamy S, Dewan VK. Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatry 2005;7:36.
45. Kim SW, Lee SY, Kim JM, et al. Resolution of tardive dyskinesia following a switch from long-acting injectable risperidone to aripiprazole: a case report and review. Clin Psychopharmacol Neurosci 2008;6:75-78.
46. Duggal HS. Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771-772.
47. Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J Clin Psychiatry 2004;65:1286-1287.
48. Saitis M, Papazisis G, Katsigiannopoulos K, et al. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia. Psychiatry Clin Neurosci 2008;62:624.